The content on this site is intended for healthcare professionals only

For the latest ecancer COVID-19 resources, click on this link

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Latest
Popular
Axicabtagene ciloleucel vs standard‑of‑care therapy for relapsed/refractory larg...
Dr Frederick Locke - Moffitt Cancer Centre, Tampa, USA
Axicabtagene ciloleucel vs standard‑of‑care therapy for relapsed/refractory large B-cell lymphoma ( Dr Frederick Locke - Moffitt Cancer Centre, Tampa, USA )
13 Dec 2021
EURO-SKI: 46% of CML patients still in molecular recurrence- and treatment-free ...
Prof Francois-Xavier Mahon - University of Bordeaux, Bordeaux, France
EURO-SKI: 46% of CML patients still in molecular recurrence- and treatment-free survival 3 years after TKIs ( Prof Francois-Xavier Mahon - University of Bordeaux, Bordeaux, France )
13 Dec 2021
Real world data supports ciltacabtagene autoleucel as effective option for tripl...
Dr Maria-Victoria Mateos - University Hospital of Salamanca-IBSAL, Salamanca, Sp...
Real world data supports ciltacabtagene autoleucel as effective option for triple-class exposed r/r MM ( Dr Maria-Victoria Mateos - University Hospital of Salamanca-IBSAL, Salamanca, Spain )
12 Dec 2021
Dara-CVRd, V-ASCT and Dara-Vrd Consolidation in UHiR NDMM and pPCL compared with...
Dr Martin Kaiser - The Institute of Cancer Research, London UK
Dara-CVRd, V-ASCT and Dara-Vrd Consolidation in UHiR NDMM and pPCL compared with myeloma XI/XI+ Trial treatment for Uhir MM ( Dr Martin Kaiser - The Institute of Cancer Research, London UK )
12 Dec 2021
Monoclonal antibody-based quadruplet therapy, AHCT and MRD response-adapted cons...
Prof Luciano Costa - University of Alabama at Birmingham, Birmingham, USA
Monoclonal antibody-based quadruplet therapy, AHCT and MRD response-adapted consolidation therapy gives highest rate of MRD negativity in NDMM ( Prof Luciano Costa - University of Alabama at Birmingham, Birmingham, USA )
12 Dec 2021
Latest in combination therapy for NDMM patients
Prof Luciano Costa - University of Alabama at Birmingham, Birmingham, USA
Latest in combination therapy for NDMM patients ( Prof Luciano Costa - University of Alabama at Birmingham, Birmingham, USA )
12 Dec 2021
Antibody and T-cell responses to COVID-19 vaccination in myeloproliferative neop...
Dr Chi-Joan How - Brigham and Women's Hospital, Boston, USA
Antibody and T-cell responses to COVID-19 vaccination in myeloproliferative neoplasm patients ( Dr Chi-Joan How - Brigham and Women's Hospital, Boston, USA )
11 Dec 2021
Potentially targetable pathways ID’d for augmenting CAR-T cell therapy for DLBCL
Prof Brian Hill - Cleveland Clinic, Cleveland, USA
Potentially targetable pathways ID’d for augmenting CAR-T cell therapy for DLBCL ( Prof Brian Hill - Cleveland Clinic, Cleveland, USA )
11 Dec 2021
Mosunetuzumab induces deep and durable remissions in 3L R/R follicular lymphoma
Prof Elizabeth Budde - City of Hope, Duarte, USA
Mosunetuzumab induces deep and durable remissions in 3L R/R follicular lymphoma ( Prof Elizabeth Budde - City of Hope, Duarte, USA )
11 Dec 2021
Initial treatment options for relapsed/refractory multiple myeloma patients
Dr Maria-Victoria Mateos - University Hospital of Salamanca-IBSAL, Salamanca, Sp...
Initial treatment options for relapsed/refractory multiple myeloma patients ( Dr Maria-Victoria Mateos - University Hospital of Salamanca-IBSAL, Salamanca, Spain )
11 Dec 2021
ZUMA-5 update: Axicabtagene ciloleucel continues to show strong effect in R/R iN...
Prof Sattva Neelapu - The University of Texas MD Anderson Cancer Center, Houston...
ZUMA-5 update: Axicabtagene ciloleucel continues to show strong effect in R/R iNHL ( Prof Sattva Neelapu - The University of Texas MD Anderson Cancer Center, Houston, USA )
11 Dec 2021
Lisocabtagene maraleucel demonstrates improvement over standard of care in 2L LB...
Dr Manali Kamdar - The University of Colorado Anschutz Medical Campus, Aurora, U...
Lisocabtagene maraleucel demonstrates improvement over standard of care in 2L LBCL ( Dr Manali Kamdar - The University of Colorado Anschutz Medical Campus, Aurora, USA )
11 Dec 2021

More from ecancer

Stay up to date with our ecancer newsletter

Learn more

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

Learn more

Support ecancer's work by making a donation